REPLIMUNE LIMITED
Get an alert when REPLIMUNE LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-12-31 (in 7mo)
Last filed for 2025-03-31
Confirmation statement due
2026-04-01
Overdue
Watchouts
Cash
USD 2,393,424
+36.6% vs 2024
Net assets
USD 9,958,411
-6.7% vs 2024
Employees
68
+4.6% vs 2024
Profit before tax
USD -216,465,950
-6.3% vs 2024
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Confirmation statement overdue
Due 2026-04-01.
Net assets
6-year trend · vs Health Care median
Accounts
6-year trend · latest reflected 2025-03-31
| Metric | Trend | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|---|---|---|---|
| Turnover | — | — | — | — | — | — | |
| Operating profit | — | — | — | — | USD -203,306,680 | USD -216,256,326 | |
| Profit before tax | — | — | — | — | USD -203,564,031 | USD -216,465,950 | |
| Net profit | — | — | — | — | USD -201,644,487 | USD -214,693,315 | |
| Cash | — | — | — | — | USD 1,752,703 | USD 2,393,424 | |
| Total assets less current liabilities | — | — | — | — | USD 85,887,626 | USD 44,901,670 | |
| Net assets | — | — | — | — | USD 10,677,474 | USD 9,958,411 | |
| Equity | -£9,273,863 | -£1,662,725 | -£12,660,392 | -£26,352,439 | USD -75,210,152 | USD -34,943,259 | |
| Average employees | — | — | — | — | 65 | 68 | |
| Wages | — | — | — | — | USD 3,865,832 | USD 4,814,172 | |
| Directors' remuneration | — | — | — | — | USD 1,415,281 | USD 152,228 |
Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2024 → FY2025 · period ending 2025-03-31 vs 2024-03-31
-
Turnover
—
Not reported
-
Cash
+36.6%
USD 1,752,703 USD 2,393,424
-
Net assets
-6.7%
USD 10,677,474 USD 9,958,411
-
Employees
+4.6%
65 68
-
Operating profit
-6.4%
USD -203,306,680 USD -216,256,326
-
Profit before tax
-6.3%
USD -203,564,031 USD -216,465,950
-
Wages
+24.5%
USD 3,865,832 USD 4,814,172
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|---|---|---|---|
| Return on capital employed | — | — | — | — | -236.7% | -481.6% | |
| Gearing (liabilities / total assets) | — | — | — | — | 0.0% | 0.0% | |
| Current ratio | — | — | — | — | 0.12x | 0.22x | |
| Interest cover | — | — | — | — | -651.28x | -772.80x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The ability of the Company to continue as a going concern is contingent on the ongoing viability of the ultimate parent company. The Company has received assurances that it will receive financial support from Replimune Group, Inc.”
Group structure
- REPLIMUNE LIMITED · parent
- Replimune (Ireland) Limited 100%
Significant events
- “RP1 product submitted for US Biological License Application, granted expedited review, PDUFA date July 2025. Re-submission on 20 Oct 2025, new PDUFA date 10 April 2026.”
- “RP2 phase 1 and 2 trials initiated for HCC and uveal melanoma.”
- “Parent company established a manufacturing facility in Framingham, Massachusetts in the USA for the manufacture of RP1, RP2 and RP3.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 9 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| GLIDDEN, Shawn | Director | 2024-10-04 | Jan 1971 | American |
| HILL, Emily | Director | 2024-10-04 | Jan 1980 | American |
| PATEL, Sushil | Director | 2024-10-04 | Feb 1971 | American |
Show 9 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| JORDAN COMPANY SECRETARIES LIMITED | Corporate Secretary | 2015-03-18 | 2015-05-07 |
| ASTLEY-SPARKE, Philip | Director | 2015-03-18 | 2024-10-04 |
| BOORSMA, Marco, Dr | Director | 2015-05-08 | 2015-09-16 |
| COFFIN, Robert Stuart, Dr | Director | 2015-03-18 | 2017-07-10 |
| LIM, Richard | Director | 2015-05-08 | 2015-09-16 |
| LOVE, Colin | Director | 2017-07-10 | 2024-10-04 |
| RHODES, Jason Paul | Director | 2015-09-16 | 2017-07-10 |
| SLOOTWEG, Hugo Alexander | Director | 2015-05-08 | 2017-07-10 |
| STAMPACCHIA, Otello | Director | 2015-05-08 | 2017-07-10 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Replimune Group, Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-07-23 | Active |
Filing timeline
Last 20 of 69 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-11-09 RESOLUTIONS Resolution
- 2024-11-09 MA Memorandum articles
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-25 | AA | accounts | Accounts with accounts type full | |
| 2026-02-11 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-03-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-11-09 | RESOLUTIONS | resolution | Resolution | |
| 2024-11-09 | MA | incorporation | Memorandum articles | |
| 2024-10-31 | TM01 | officers | Termination director company with name termination date | |
| 2024-10-31 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-31 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-31 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-31 | TM01 | officers | Termination director company with name termination date | |
| 2024-09-05 | AA | accounts | Accounts with accounts type full | |
| 2024-06-04 | AAMD | accounts | Accounts amended with accounts type full | |
| 2024-05-02 | AA | accounts | Accounts with accounts type full | |
| 2024-04-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-03-07 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2023-05-03 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2023-05-02 | PSC09 | persons-with-significant-control | Withdrawal of a person with significant control statement | |
| 2023-03-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-10-31 | AA | accounts | Accounts with accounts type full | |
| 2022-10-18 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.